Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HYTN Innovations Inc C.HYTN

Alternate Symbol(s):  HYTNF

HYTN Innovations Inc. is a Canada-based company that creates products containing psychoactive and psychotropic compounds, including cannabinoids derived from cannabis. It formulates, manufactures, markets, and sells cannabis goods. It is engaged in the development of the sparkling tetrahydrocannabinol and the cannabidiol beverage business. All its sparkling cannabis beverages contain 10 milligrams (mg) of THC and are made using its process, Elevation Technology. Its products include Rosewater Lemonade, Watermelon Mint, Lemongrass Ginger, and Blood Orange. Its Rosewater Lemonade is a sugar-free exploration of citrus accented with floral notes. Blood Orange is formulated to bring out the sweet flavors found in this seasonal citrus fruit. The Company is also focused on the research and development of psychedelic and psychoactive compounds, with a particular emphasis on enhancing tryptamine yields in psychedelic mushrooms. It has a manufacturing facility based in Kelowna, British Columbia.


CSE:HYTN - Post by User

Post by Betteryear2on Jun 27, 2024 8:16am
71 Views
Post# 36108517

HYTN Awarded Drug Establishment License

HYTN Awarded Drug Establishment LicenseVANCOUVER, British Columbia, June 27, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has been granted a Drug Establishment License (DEL) by Health Canada. This license allows HYTN to engage in the GMP fabrication, packaging, and labeling of non-sterile pharmaceuticals containing both cannabis and psilocybin, significantly enhancing the Company's capabilities and expanding its market reach. With this license, HYTN is now positioned to manufacture and export these pharmaceutical products into regulated global markets, further solidifying its status as one of the very few companies in the sector with these capabilities.

HYTN Awarded Drug Establishment License from Health (globenewswire.com)
<< Previous
Bullboard Posts
Next >>